HIV Non-Occupational Post-Exposure Prophylaxis (nPEP) and Processes of Patient Care

Marie Dorsey, Pharm.D., BCPS, AAHIVP
Inpatient Pharmacist, PeaceHealth
HIV Alliance Board of Directors

Last Updated: August 27, 2020
No conflicts of interest or relationships to disclose
Overview

• nPEP Guidelines
• Medication regimens
• In-practice barriers to nPEP
• Obtaining and payment for nPEP medication
• Possible process solutions
• nPEP resources
**nPEP DHHS Guidelines-April 2016**

<table>
<thead>
<tr>
<th>PEP STEPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate to high risk exposure → start nPEP</td>
</tr>
<tr>
<td>Start nPEP ≤ 72hs after exposure for greatest benefit</td>
</tr>
<tr>
<td>HIV Ag/Ab or Ab rapid test</td>
</tr>
<tr>
<td>Screening for other STIs, HepC, HepB, pregnancy</td>
</tr>
<tr>
<td>Determine regimen (all contain 3 drugs and taken 28 days total)</td>
</tr>
<tr>
<td>Follow up to determine tolerability, adherence, necessity, labs</td>
</tr>
</tbody>
</table>

See Dr. Harrington’s ECHO PEP Presentation (May 2016) on MWAETC ECHO YouTube page at [https://youtu.be/Aj2PwEMpnQI](https://youtu.be/Aj2PwEMpnQI)

Estimated Per-Act Risk for Acquiring HIV From an Infected Source, by Exposure Act

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th>Rate for HIV acquisition per 10,000 exposures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion</td>
<td>9,250</td>
</tr>
<tr>
<td>Receptive anal intercourse</td>
<td>138</td>
</tr>
<tr>
<td>Needle sharing during injection drug use</td>
<td>63</td>
</tr>
<tr>
<td>Percutaneous (needlestick)</td>
<td>23</td>
</tr>
<tr>
<td>Insertive anal intercourse</td>
<td>11</td>
</tr>
<tr>
<td>Receptive penile-vaginal intercourse</td>
<td>8</td>
</tr>
<tr>
<td>Insertive penile-vaginal intercourse</td>
<td>4</td>
</tr>
<tr>
<td>Receptive or insertive oral intercourse</td>
<td>Low</td>
</tr>
<tr>
<td>Biting, spitting, throwing fluids, sharing sex toys</td>
<td>Negligible (technically possible, but unlikely and not well documented)</td>
</tr>
</tbody>
</table>
# nPEP 28-day Regimens

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>Preferred/alternative</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults and adolescents ≥ 13yrs, including pregnant women, CrCl &gt; 60</td>
<td>Preferred</td>
<td>TDF/FTC + RAL or DTG*</td>
</tr>
<tr>
<td>Adults and adolescents ≥ 13yrs, including pregnant women, CrCl ≤ 59</td>
<td>Preferred</td>
<td>AZT/3TC + RAL or DTG*</td>
</tr>
<tr>
<td>Children 2-12yr</td>
<td>Preferred</td>
<td>TDF/FTC + RAL</td>
</tr>
<tr>
<td>Children 4wk-2yr</td>
<td>Preferred</td>
<td>AZT/3TC + RAL or r/LPV</td>
</tr>
<tr>
<td>Children birth-4wk</td>
<td>Call pediatric specialist</td>
<td></td>
</tr>
</tbody>
</table>

*DHHS Adult and Adolescent GL (Dec 2019): DTG as *Alternative* (instead of *Not Recommended*) for initial therapy in women of childbearing age.
DHHS Perinatal GL (Dec 2019): DTG as *Preferred* in *all* pregnant women, regardless of gestational age and *Alternative* in women trying to conceive.
Patient Case: Alice

- 24yr old female presents to the ED 73hrs after several high-risk sexual encounters at a party, and does not use contraception because she “wouldn’t mind getting pregnant”. She does not like taking medication. It is Friday night.

- Interactive Q: What would you give her for nPEP?
  A. Nothing, it’s past 72hrs
  B. TDF/FTC + RAL
  C. TDF/FTC + DTG
  D. Phone a friend (expert to expert consultation)
Patient Case: Alice Continued

Friday
-Alice and provider decide on TDF/FTC + DTG
-Gets 1st dose from ED pharmacy AND 3-day nPEP take-home pack
-2 prescriptions are written for 30 days

Monday
-PrEP/PEP coordinator calls Alice (ED RN had Alice fill out ROI and left message for coordinator)
-PrEP/PEP coordinator and Alice fill out PAP applications online & by phone
-Monday afternoon PAP apps approved, and funds sent to pharmacy for filling
-Pharmacy must order medications for next day fill

Tuesday
-Alice picks up medication and takes 5th dose
nPEP in Practice: Barriers Follow-Up of Patient

- Adherence to taking full PEP regimen = 40-57%
  - Lowest = adolescents, sexual assault, female

- Less likely to follow up at clinic:
  - Older age
  - Out of pocket payment (no insurance)
  - Sexual assault

- Starter packs vs full 28-day regimen dispensed:
  - Outcomes better when offered full 28-day course at presentation (fewer refusals, higher completion rates)

- Patient’s mental health prevents follow up

nPEP in Practice: Barriers

Providers are not consistently prescribing nPEP

- Protocol and procedures not available
- Concern of drug side effects and viral resistance
  - nPEP guidelines not used
- Appropriate level of exposure risk not determined
  - Assuming HIV is not a problem

Crow, A. Infect Dis Society of Am 2013 (137): presentation 1138
nPEP in Practice: Barriers
MWAETC nPEP Survey in Oregon

- Aim: determine nPEP barriers to access across urban and rural emergency departments and urgent care facilities
- 42 Emergency Departments, 63 Urgent Care managers and charge nurses surveyed across Oregon 6/2019 to 1/2020

Conclusions:

✓ Lack of nPEP practices, policies, and procedures, for high-risk exposure outside of sexual assault
✓ Poor communication within facilities, across health systems, and to external partners
✓ Low familiarity with nPEP community resources
✓ Prescribing that did not align with CDC guidelines

There is a significant need for training and education within Oregon Emergency Departments and Urgent Care Facilities
nPEP in Practice:
Obtaining Medication

- Most Emergency Departments will have usual nPEP meds as 3-day take-home pack
- Pharmacies have HIV medications that are contracted with state ADAP
- Call patient’s pharmacy ahead of time
  - Is medication in stock already?
  - Do you have to order medication and when will it be available?
  - Support staff will need to call pharmacy before patient visits
Where To Find the nPEP Meds: AIDS Drug Assistance Programs (ADAPs)

<table>
<thead>
<tr>
<th>State</th>
<th>ADAP</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska</td>
<td>Alaska ADAP</td>
<td><a href="https://www.alaskanaids.org/client-services/aids-drug-assistance-program-adap">https://www.alaskanaids.org/client-services/aids-drug-assistance-program-adap</a></td>
</tr>
<tr>
<td>Idaho</td>
<td>Idaho AIDS Drug Assistance Program (IDAGAP)</td>
<td><a href="https://healthandwelfare.idaho.gov/Health/HIV,STD,Hepatitis">https://healthandwelfare.idaho.gov/Health/HIV,STD,Hepatitis</a> Section/HIVCare/tabid/391/Default.aspx</td>
</tr>
<tr>
<td>Oregon</td>
<td>CAREAssist</td>
<td><a href="http://www.ramsellcorp.com/individuals/or.aspx">http://www.ramsellcorp.com/individuals/or.aspx</a></td>
</tr>
<tr>
<td>Washington</td>
<td>Early Intervention Program (EIP)</td>
<td><a href="http://www.ramsellcorp.com/individuals/wa.aspx">http://www.ramsellcorp.com/individuals/wa.aspx</a></td>
</tr>
</tbody>
</table>

Search for city under pharmacy locators on each ADAP website or call ADAP phone number to obtain pharmacy list.
Pharmacist Prescribing nPEP in Oregon

• Oregon Board of Pharmacy approved pharmacist prescribing of nPEP with conditions (Aug 2020):
  - Continuing education (nPEP and trauma informed care)
  - State approved protocol use required
  - Geared toward retail pharmacists

• Improved access to evaluation, medication and follow up

• PrEP pharmacist prescribing may happen the near future
Payment for nPEP

- Each nPEP regimen~$4000.00 for one-month supply (without insurance)

- Private Insurance
  - Expect expensive cost-sharing
  - Consider deductibles, co-pays, prior authorizations, formulary restrictions

- Patient Assistance Programs (PAPs)
  - Manufacturer and non-manufacturer PAPs

Most patients will need assistance figuring out payment and filling out PAP applications
# Manufacturer Patient Assistance Programs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Contact</th>
<th>Website</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tivicay (Dolutegravir)</strong></td>
<td>Viiv Connect</td>
<td>Ph:844-588-3288 M-F 8am-11pm EST</td>
<td><a href="https://www.viivconnect.com/portal/">https://www.viivconnect.com/portal/</a></td>
<td>1. Call or enroll online (24hr) 2. Receive voucher number and give to pharmacy <em>cannot have Medicare part D coverage</em></td>
</tr>
<tr>
<td><strong>Isentress (Raltegravir)</strong></td>
<td>Merck “Merck’s Support”</td>
<td>Ph:800-727-5400 Fax: 800-528-2551 M-F 8am-8pm EST</td>
<td><a href="https://www.merckhelps.com/docs/MPAP_Enrollment_Form_English.pdf">https://www.merckhelps.com/docs/MPAP_Enrollment_Form_English.pdf</a></td>
<td>1. Provider and patient complete app together 2. Fax app with &quot;Urgent&quot; or “PEP” written on top -if form submitted by 2:30pm EST, med will be delivered to patient’s home by 1:30pm EST next day</td>
</tr>
</tbody>
</table>

This information subject to change. Contact each program directly to verify current process. Updated Oct 2019
Setting nPEP Providers and Patients Up for Success

• Write nPEP procedures and protocols

• Provide ongoing education of ED, UC and clinic staff regarding nPEP use, availability

• Encourage use of nPEP guidelines

• Ensure warm hand-off to follow-up provider (someone to call patient)

• Connect with community resources and find PrEP/PEP coordinator

• Provide full 28-day regimen at presentation

• Write nPEP prescriptions for 30-day supply (or pharmacy may not fill)

• Offer prescriptions for supportive medications (nausea, insomnia)

• Find PAP application champion (PrEP/PEP coordinator, SARN, social work, MA, pharmacist)
Conclusions: PEP Talk

Set up providers, care-team, and patients up for success:

✓ nPEP protocols need to be written, communicated and followed
✓ Find the unique barriers each system
✓ Determine community partners and collaborate with them
✓ Assist patients on how to access and fund their medication

HIV providers (HIV ECHO attendees) will help detect and remove barriers so patients may have improved access to nPEP
nPEP Resources

• AETC nPEP Toolkit at https://aidsetc.org/resource/non-occupational-post-exposure-prophylaxis-npep-toolkit

• National HIV Curriculum (Nonoccupational HIV Post-Exposure Prophylaxis at https://www.hiv.uw.edu/custom/prevention/nonoccupational-postexposure-prophylaxis/summary

• National Clinician Consultation Center PEPline
  - 888-448-4911 (M-F 9am-8pm, SS & holidays 11am-8pm)
  - https://nccc.ucsf.edu/clinician-consultation/pep-post-exposure-prophylaxis/
References


- Crow, A., Ahmed, T., Kumar, R., Katner, H.P., Statewide Survey of Emergency Department Practice for Prophylaxis of Sexually Transmitted Infections in Rape Victims. Infectious Diseases Society of America, October 4, 2013, Session 137:Presentation 113


- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV—Department of Health and Human Services, United States, December 2019


- Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States, US Department of Health and Human Services, April 4, 2020

- Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—Department of Health and Human Services, United States, 2016

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.